Bionano Genomics (BNGO) Osake Kurssi

Bionano Genomics Inc is a life sciences company headquartered in San Diego, United States. The company operates within the Health Care sector, specifically in the Life Sciences Tools & Services industry. It went public through an IPO on August 1, 2018, and currently employs 95 people. Bionano Genomics develops and markets the Saphyr system, a platform designed for detecting structural variations in genomes with high sensitivity and specificity. The Saphyr system enables researchers and clinicians to study chromosomal changes, known as cytogenetics, and to identify new diagnostic and therapeutic targets. The company also offers sequencing solutions for discovery research, primarily focused on identifying single nucleotide variations associated with diseases or therapeutic responses. Bionano Genomics does not provide specific details about its subsidiary Lineagen, Inc. or mention any other products beyond the Saphyr system and sequencing for discovery research. The company's website is bionanogenomics.com, where further information about its services and technology can be found. Bionano Genomics operates as a publicly traded company with the ticker symbol BNGO and ISIN US09075F4046. It is important to note that the company's employee count is 95, not 147 as mentioned in some unverified sources. The company's primary focus is on advancing genomic analysis tools to support clinical and research applications in the life sciences field.